135 related articles for article (PubMed ID: 37114359)
81. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
82. Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Pagkali A; Mamais I; Michalinos A; Agouridis AP
Curr Oncol; 2022 Jan; 29(1):321-336. PubMed ID: 35049703
[TBL] [Abstract][Full Text] [Related]
83. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
[TBL] [Abstract][Full Text] [Related]
84. A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Shi T; Yin S; Zhu J; Zhang P; Liu J; Zhu Y; Wu S; Chen X; Wang X; Teng Y; Zhu T; Yu A; Zhang Y; Feng Y; Huang H; Bao W; Li Y; Jiang W; Zhang P; Li J; Ai Z; Zhang W; Jia H; Zhang Y; Jiang R; Zhang J; Gao W; Luan Y; Zang R
J Gynecol Oncol; 2020 May; 31(3):e61. PubMed ID: 32319233
[TBL] [Abstract][Full Text] [Related]
85. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
[TBL] [Abstract][Full Text] [Related]
86. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
87.
Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
[TBL] [Abstract][Full Text] [Related]
88. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
89. Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
Cowan R; Nobre SP; Pradhan N; Yasukawa M; Zhou QC; Iasonos A; Soslow RA; Arnold AG; Trottier M; Catchings A; Roche KL; Gardner G; Robson M; Abu Rustum NR; Aghajanian C; Cadoo K
Gynecol Oncol; 2021 May; 161(2):521-526. PubMed ID: 33712278
[TBL] [Abstract][Full Text] [Related]
90. Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis.
Wang Y; Li N; Ren Y; Zhao J
J Obstet Gynaecol Res; 2022 Sep; 48(9):2270-2284. PubMed ID: 35698734
[TBL] [Abstract][Full Text] [Related]
91. Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
Gorodnova TV; Kotiv KB; Ivantsov AO; Mikheyeva ON; Mikhailiuk GI; Lisyanskaya AS; Mikaya NA; Guseynov KD; Bondarev NE; Matveyeva NS; Nekrasova EA; Sidoruk AA; Roman LD; Manikhas GM; Belyaev AM; Sokolenko AP; Berlev IV; Imyanitov EN
Int J Gynecol Cancer; 2018 Oct; 28(8):1498-1506. PubMed ID: 30247247
[TBL] [Abstract][Full Text] [Related]
92. The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.
Tadić V; Zhang W; Brozovic A
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189052. PubMed ID: 38097143
[TBL] [Abstract][Full Text] [Related]
93. Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report.
Yuan H; Zhang R; Li N; Yao H
Hered Cancer Clin Pract; 2024 Feb; 22(1):2. PubMed ID: 38360632
[TBL] [Abstract][Full Text] [Related]
94. Serum Creatinine Elevation as a Risk Factor for Niraparib-induced Hematologic Toxicity.
Hashimoto K; Kawakami K; Yokokawa T; Shibata N; Soejima A; Sugisaki T; Mori Y; Shimizu H; Yunokawa M; Kanao H; Yamaguchi M
Anticancer Res; 2023 Oct; 43(10):4533-4541. PubMed ID: 37772578
[TBL] [Abstract][Full Text] [Related]
95. Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
Inno A; Picece V; Bogina G; Settanni G; Viassolo V; Salgarello M; Gori S
Clin Lung Cancer; 2024 Mar; 25(2):175-179. PubMed ID: 38008640
[No Abstract] [Full Text] [Related]
96. Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of
Li D; Song Y; Bai Z; Xi X; Liu F; Zhang Y; Qin C; Du D; Du Q; Liu S
Antibiotics (Basel); 2023 Jun; 12(7):. PubMed ID: 37508205
[TBL] [Abstract][Full Text] [Related]
97. Application of Paper-Based Microfluidic Analytical Devices (µPAD) in Forensic and Clinical Toxicology: A Review.
Musile G; Grazioli C; Fornasaro S; Dossi N; De Palo EF; Tagliaro F; Bortolotti F
Biosensors (Basel); 2023 Jul; 13(7):. PubMed ID: 37504142
[TBL] [Abstract][Full Text] [Related]
98. Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Treatment of Severe Essential Tremor in a Lung Transplant Recipient-A Case Report.
Modi P; Qiu L; Fallah T; Courtwright A; Halpern CH
Transplant Proc; 2023 Oct; 55(8):1988-1990. PubMed ID: 37495484
[TBL] [Abstract][Full Text] [Related]
99. The effect of hydrochlorothiazide on the recurrence of nonmelanoma skin cancer: a 7-year retrospective study comprising 300 patients.
Özkan B; Savran S; Akıncı K; Albayati A; Uysal Pİ; Uysal AÇ
Turk J Med Sci; 2023 Jun; 53(3):760-752. PubMed ID: 37476909
[TBL] [Abstract][Full Text] [Related]
100. Metastatic colon cancer treated using traditional Chinese medicine combined with chemotherapy: A case report.
Deng CG; Tang MY; Pan X; Liu ZH
World J Clin Cases; 2023 Jul; 11(19):4670-4676. PubMed ID: 37469725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
